Published: February 2, 2017

Introduction {#sec1}
============

Human bone marrow stromal cells (hBMSCs) are non-hematopoietic multipotent cells capable of differentiation into mesodermal cell types such as osteoblasts (OBs) and adipocytes (ADs) ([@bib1]). It is increasingly recognized that secreted factors have an important role in mediating hBMSC function to actively maintain homeostasis of skeletal tissue. In addition, secreted proteins mediate the observed therapeutic effects of hBMSCs on enhancing regeneration of skeletal ([@bib30]), cardiac ([@bib28]), dermal ([@bib8]), and neural ([@bib64]) tissues. Characterizing the functions of proteins secreted by hBMSCs is a pre-requisite for understanding the mechanisms of their therapeutic effects and their role in tissue homeostasis in normal and disease states.

We recently reported a profile of hBMSC-secreted factors at different stages of ex vivo OB differentiation using a quantitative proteomic analysis based on stable isotope labeling by amino acids in cell culture ([@bib36]). Among the differentially regulated proteins during OB differentiation, we identified legumain as a secreted protein that has not been previously implicated in hBMSC biology.

Legumain (also known as asparaginyl endopeptidase, *AEP*), encoded by the *LGMN* gene, is a broadly expressed lysosomal cysteine protease that is secreted as inactive prolegumain (56 kDa) and processed into enzymatically active 46 and 36 kDa forms, as well as a 17 kDa enzymatically inactive C-terminal fragment. Legumain directly regulates diverse physiological and pathological processes by remodeling tissue-specific targets (e.g., extracellular matrix \[ECM\] components, enzymes, receptors) ([@bib11], [@bib14], [@bib19], [@bib21], [@bib22], [@bib43], [@bib45], [@bib47], [@bib48], [@bib49], [@bib51], [@bib55], [@bib59]). In addition, legumain indirectly contributes to atherosclerotic plaque instability through activation of cathepsin L in the arterial ECM ([@bib14], [@bib35], [@bib47], [@bib51]). Surprisingly, the non-enzymatic 17 kDa C-terminal fragment is also biologically active and inhibits osteoclast differentiation through binding to an uncharacterized receptor ([@bib12], [@bib13]).

Here we report the role of legumain in regulating the differentiation fate of hBMSCs. Using cell-based and in vivo studies we show that legumain inhibited OB differentiation through degradation of fibronectin. During development, legumain-deficient zebrafish exhibited precocious bone formation and mineralization. Finally, abnormal expression and cellular localization of legumain was observed in bone biopsies obtained from patients with postmenopausal osteoporosis. Together, the present study reveals role of legumain in determining the differentiation fate of BMSCs thereby regulating bone formation.

Results {#sec2}
=======

Legumain Expression and Activity Are Regulated during hBMSC Differentiation In Vitro and In Vivo {#sec2.1}
------------------------------------------------------------------------------------------------

To assess cellular localization and regulation of legumain (*LGMN*) expression during OB differentiation under normal physiological conditions, we first performed histological analysis of adult human iliac crest bone biopsies. Legumain immunoreactivity was present in osteoprogenitors near bone-forming surfaces which included perivascular, canopy, and reversal cells ([Figure 1](#fig1){ref-type="fig"}A) ([@bib18], [@bib37]). We did not detect immunoreactivity in mature OBs, osteocytes, or osteoclasts ([Figure 1](#fig1){ref-type="fig"}A). Legumain mRNA showed a similar expression pattern ([Figure 1](#fig1){ref-type="fig"}B). Next, we examined legumain expression and activity during ex vivo OB differentiation of hBMSCs. *LGMN* mRNA expression increased ([Figure 1](#fig1){ref-type="fig"}C) and the mature *LGMN* protein (36 kDa) accumulated ([Figures 1](#fig1){ref-type="fig"}D and 1E) during the early commitment phase (days 1--6) and were downregulated during the late maturation phase (days 6--18) of OB differentiation. Correspondingly, legumain enzymatic activity was reduced in differentiated OBs ([Figure 1](#fig1){ref-type="fig"}F). In contrast, *LGMN* mRNA expression and protein levels were increased during AD differentiation of hBMSCs ([Figures 1](#fig1){ref-type="fig"}G--1I).

Legumain Deficiency Enhances OB Differentiation and Impairs AD Differentiation of hBMSCs {#sec2.2}
----------------------------------------------------------------------------------------

We employed lentiviral transduction to generate hBMSC lines with stable expression of *LGMN* shRNA (sh*LGMN*) or a non-targeting control (shCtrl). sh*LGMN* significantly reduced legumain mRNA, protein, and activity levels ([Figures 2](#fig2){ref-type="fig"}A--2C). In addition, *LGMN* knockdown reduced hBMSC proliferation ([Figure S1](#mmc1){ref-type="supplementary-material"}A). After 6 days under osteogenic culture conditions, *LGMN* knockdown did not alter alkaline phosphatase (*ALP*) activity ([Figure 2](#fig2){ref-type="fig"}D), or expression of the early OB commitment markers *ALP* and collagen 1 alpha 1 chain (*Col1a1*), but significantly upregulated the expression of the late OB maturation markers bone gamma-carboxyglutamate protein (*BGLAP*) and integrin binding sialoprotein (*IBSP*) ([Figure 2](#fig2){ref-type="fig"}E). Moreover, *LGMN* knockdown enhanced the formation of mineralized ECM, as shown by the increased extent and intensity of alizarin red staining ([Figure 2](#fig2){ref-type="fig"}F). In contrast, *LGMN* knockdown inhibited AD differentiation ([Figures 2](#fig2){ref-type="fig"}G and 2H) and reduced expression of the AD maker genes: peroxisome proliferator-activated receptor gamma 2 (*PPARG2*), fatty acid binding protein 4 (*FABP4*) and adiponectin, C1Q and collagen domain containing (*ADIPOQ*) ([Figure 2](#fig2){ref-type="fig"}I) under adipogenic culture conditions. To determine whether *LGMN* knockdown stimulated OB differentiation and bone-forming capacity in vivo, sh*LGMN* or shCtrl cells were mixed with hydroxyapatite/tricalcium phosphate granules as an osteoconductive carrier, and implanted subcutaneously in immune-deficient mice. Histological analysis of the implants after 8 weeks revealed a significant 2-fold increase in the amount of heterotopic bone formed by the sh*LGMN* compared with the control (shCtrl) cells ([Figures 2](#fig2){ref-type="fig"}J and 2K). Human-specific vimentin staining showed that the heterotopic bone was generated by the transplanted hBMSCs ([Figure 2](#fig2){ref-type="fig"}L).

Pharmacological Inhibition of Legumain Activity Enhances OB Differentiation and Impairs AD Differentiation of hBMSCs {#sec2.3}
--------------------------------------------------------------------------------------------------------------------

To determine whether legumain proteolytic activity is required for its effects on hBMSCs differentiation, we employed a small-molecule legumain inhibitor (SD-134) ([@bib38]). hBMSC cultures incubated for 24 hr with SD-134 (50--500 nM) exhibited significant legumain inhibition ([Figure S1](#mmc1){ref-type="supplementary-material"}B), but no effect on cell number was observed during 12 days treatment ([Figure S1](#mmc1){ref-type="supplementary-material"}C). During in vitro OB differentiation of hBMSCs, SD-134 (50 nM) treatment did not induce significant changes in *ALP* activity ([Figure S1](#mmc1){ref-type="supplementary-material"}D), but enhanced formation of mineralized matrix ([Figure S1](#mmc1){ref-type="supplementary-material"}E). In contrast, SD-134 treatment inhibited AD differentiation ([Figures S1](#mmc1){ref-type="supplementary-material"}F and S1G).

Overexpression of LGMN Impairs OB Maturation and Enhances AD Differentiation of hBMSCs {#sec2.4}
--------------------------------------------------------------------------------------

To determine whether increased *LGMN* activity actively blocks OB differentiation, we employed a retroviral transduction system to establish hBMSCs stably overexpressing full-length *LGMN* (hBMSC-*LGMN*) or an empty vector control (hBMSC-EV). *LGMN* overexpression was confirmed by mRNA, protein, and activity measurements ([Figures 3](#fig3){ref-type="fig"}A--3C). The levels of fully processed and activated legumain protein (36 kDa) were increased in lysates from hBMSC-*LGMN* cells ([Figures 3](#fig3){ref-type="fig"}B and 3C). In addition, secreted prolegumain (56 kDa) was detected in the conditioned media from hBMSC-*LGMN* cells ([Figures 3](#fig3){ref-type="fig"}D and 3E). In contrast to *LGMN* knockdown, hBMSC-*LGMN* exhibited increased cell proliferation ([Figure S1](#mmc1){ref-type="supplementary-material"}H), impaired OB maturation, demonstrated by decreased late OB marker gene expression (*BGLAP*, *IBSP*), and decreased mineralized matrix formation, whereas expression of early OB commitment markers (*ALP*, *Col1a1*) was not altered by *LGMN* overexpression ([Figures 3](#fig3){ref-type="fig"}F and 3G). hBMSC-*LGMN* cells also exhibited enhanced AD differentiation ([Figures 3](#fig3){ref-type="fig"}H and 3I), and enhanced expression of AD marker genes (*PPARG2*, *FABP4*, and *ADIPOQ*) ([Figure 3](#fig3){ref-type="fig"}J). Thus, increased *LGMN* activity biases hBMSC differentiation to non-OB fates.

Legumain Degrades Fibronectin during hBMSC Differentiation {#sec2.5}
----------------------------------------------------------

Since ECM proteins play an important role in OB differentiation ([@bib31]) and fibronectin functions as a master organizer of ECM biogenesis ([@bib26]), we tested whether the effect of legumain on hBMSC differentiation is mediated through regulation of fibronectin levels. Lysates from legumain-deficient and legumain-overexpressing cells during in vitro OB differentiation showed an inverse relationship between the protein levels of mature legumain (36 kDa) and fibronectin ([Figures 4](#fig4){ref-type="fig"}A--4F). Fibronectin mRNA (*FN1*) levels did not change during OB differentiation ([Figure S2](#mmc1){ref-type="supplementary-material"}A), which is consistent with post-transcriptional regulation. Incubation of purified human fibronctin with lysates from legumain-overexpressing HEK293 cells ([@bib58]) confirmed that fibronectin is degraded by a legumain-dependent process in a dose- and time-dependent manner ([Figure S2](#mmc1){ref-type="supplementary-material"}B). The fibronectin-degrading activity was also present in lysates from *LGMN*-overexpressing hBMSCs ([Figure 4](#fig4){ref-type="fig"}G). To determine whether intact fibronectin is required for OB differentiation, we blocked *FN1* expression using siRNA, which inhibited OB maturation and formation of mineralized matrix ([Figure 4](#fig4){ref-type="fig"}H). To determine whether fibronectin degradation is sufficient to explain the inhibitory effects of legumain on OB maturation, we exposed osteogenic hBMSC cultures to a panel of purified ECM proteins (gelatin, collagen type 1, and fibronectin). Both gelatin and fibronectin enhanced the formation of mineralized matrix by control hBMSC ([Figure 4](#fig4){ref-type="fig"}I). However, only fibronectin blocked the inhibitory effect of legumain on OB differentiation and function ([Figure 4](#fig4){ref-type="fig"}J), suggesting that fibronectin is an endogenous legumain target.

Legumain-Deficient Zebrafish Exhibit Precocious OB Differentiation and Bone Mineralization {#sec2.6}
------------------------------------------------------------------------------------------

To examine the function of legumain during bone development, we targeted the essential peptidase domain within the zebrafish *lgmn* locus using transcription activator-like effector nucleases (TALENs) ([Figure 5](#fig5){ref-type="fig"}A). High-resolution melt analysis (HMRA) indicated that the *lgmn* gene was extensively modified in *lgmn*-TALEN-injected animals ([Figure 5](#fig5){ref-type="fig"}B). To quantify the extent of *lgmn* disruption, we used ON/OUT qPCR ([@bib56]) and determined that ∼84% of *lgmn* alleles were modified. We proceeded to analyze OB differentiation and function in the lgmn-TALEN-injected animals compared with non-targeted control-injected animals. At 5 days post-fertilization (dpf) *lgmn*-deficient animals exhibited increased expression of genes associated with OB differentiation, including alkaline phosphatase (*alp*) and osteopontin (*spp1*), while the expression of the adipogenic marker PPAR-gamma (*pparg*) was unchanged ([Figure 5](#fig5){ref-type="fig"}C). By 7 dpf *lgmn*-deficient zebrafish did not show any gross morphological defects ([Figure 5](#fig5){ref-type="fig"}D). However, there were approximately twice as many mineralized vertebrae in *lgmn*-TALEN-injected animals compared with controls ([Figures 5](#fig5){ref-type="fig"}E and 5F). Next, we tested whether post-embryonic OB progenitors remained sensitive to legumain activity. Zebrafish embryogenesis is complete by 3 dpf ([@bib34]). Therefore, we treated animals from 3 to 7 dpf with the legumain inhibitor SD-134. Consistent with the osteogenic effect of genetic *lgmn* disruption, SD-134-treated zebrafish exhibited an increase in the number of mineralized vertebrae at 7 dpf ([Figure 5](#fig5){ref-type="fig"}G).

Legumain Serum Levels Decrease with Aging, and Local Expression of Legumain Is Increased in the Bone Microenvironment of Osteoporotic Patients {#sec2.7}
----------------------------------------------------------------------------------------------------------------------------------------------

Legumain has recently been identified as a biomarker for diverse pathological states ([@bib7], [@bib25], [@bib41], [@bib44], [@bib61], [@bib63]). We examined serum levels of legumain in 89 women aged 48--87 years and found an inverse relationship between serum legumain levels and age ([Figure 6](#fig6){ref-type="fig"}A). To determine legumain-localized activity within the bone microenvironment, we established primary hBMSC cultures from iliac crest bone marrow aspirates. Legumain levels were significantly higher in osteoporotic patients compared with age-matched controls ([Figures 6](#fig6){ref-type="fig"}B and 6C). In addition, immunohistochemical analyses of bone biopsies from postmenopausal osteoporotic patients (n = 13) and age-matched controls (n = 11) revealed legumain overexpression in bone marrow ADs in most osteoporotic samples (8 out of 13) ([Figure 6](#fig6){ref-type="fig"}D). To determine whether legumain-overexpressing ADs affected adjacent bone formation, we measured the trabecular bone volume in 80 random regions of interest (ROI = 1 mm^2^) in osteoporotic bone biopsies. Regions with legumain-positive ADs exhibited significantly reduced trabecular bone volume and there was an inverse relationship between legumain immunoreactivity in ADs and the local trabecular bone volume (Spearman r = −0.314, p = 0.004) ([Figure 6](#fig6){ref-type="fig"}E).

Discussion {#sec3}
==========

Our findings demonstrate a physiological role of legumain in regulating bone formation and possibly bone mass, as well as a role in the pathophysiology of reduced bone mass observed in patients with postmenopausal osteoporosis. In particular, we find that legumain functions in the bone-remodeling microenvironment to inhibit OB differentiation and to enhance AD differentiation of hBMSCs, through regulation of ECM fibronectin deposition.

Our studies demonstrate that legumain inhibits late stages of ex vivo OB differentiation and the formation of mineralized ECM, suggesting that legumain regulates the ECM-hBMSC interaction that is required for the expression of the mature OB phenotype ([@bib46]). We identified fibronectin degradation as a mediator of legumain effects, similar to its role in renal proximal tubular cells, which is required for normal renal function ([@bib49]). Fibronectin is known to enhance OB differentiation through interaction with the α5β1 integrin receptor and is required for OB maturation, survival, and matrix mineralization ([@bib9], [@bib42], [@bib46], [@bib50]). In contrast, fibronectin exerts inhibitory effects on lipid accumulation and AD differentiation ([@bib6], [@bib52], [@bib60]).

Our data suggest that the proteolytic activity of legumain is important for its effects on hBMSC differentiation and bone formation. Legumain has been reported to regulate bone resorption through inhibition of osteoclast formation and function by its C-terminal fragment (17 kDa), which is enzymatically inactive, suggesting that legumain exerts protease-independent functions ([@bib12]). In addition, legumain exhibits carboxypeptidase ([@bib16]) and peptide ligase activity ([@bib17]). The possible involvement of these actions of legumain in regulating skeletal homeostasis requires further studies.

We observed that genetic loss- and gain-of-function of legumain were associated with changes in BMSC proliferation. However, regulation of BMSC proliferation by legumain is independent of its enzymatic activity, since small-molecule inhibition of legumain activity did not alter BMSC proliferation. This observation corroborates previous reports showing regulation of cell proliferation by legumain, independent of its enzymatic activity ([@bib5]). Further support of the potential role of legumain in osteoprogenitor cell proliferation is based on its colocalization with the proliferating osteoblastic cells in human bone biopsies. The proliferation status of osteoprogenitor cells near the bone-forming surfaces, as determined by immunohistochemical analysis of *Ki-67*, has been previously reported in human bone specimens ([@bib37]). Interestingly, the pattern of *Ki-67* immunoreactivity coincided with legumain expression, as the legumain-positive osteoprogenitor cells (such as canopy cells) are also *Ki-67* positive, whereas the mature osteoblastic cells (such as bone-lining cells) are both legumain negative and *Ki-67* negative.

We employed the zebrafish model to investigate the developmental and pharmacological effects of legumain inhibition in vivo. Zebrafish is an attractive model for in vivo screening studies, due to the molecular and cellular conservation of skeletal development and its predictive value when studying human diseases ([@bib23], [@bib24], [@bib29], [@bib40]). For example, mutations in zebrafish collagen type IA1 reproduce many aspects of osteogenesis imperfecta ([@bib23]), and *ptk7* mutant zebrafish have been identified as suitable models for scoliosis ([@bib24]). We extend the usefulness of this model by showing that late developmental events such as the mineralization of vertebrae are amenable to analysis in TALEN-injected animals. Our finding that legumain-deficient zebrafish exhibit enhanced OB differentiation and bone mineralization is consistent with the in vitro effects of legumain knockdown. In addition, we show that post-embryonic pharmacological inhibition of legumain recapitulates the osteogenic effects of genetic legumain ablation.

The serum levels of legumain decreased with aging, which was counterintuitive in relation to the proposed function of legumain in bone. However, the major tissue source(s) of serum legumain are not known and the decline in serum levels of legumain with aging may be connected to age-related decrease in renal function that may influence both clearance and production of legumain (the kidneys could be a major source of circulating legumain, but this is not clear at the moment). Thus, direct examination of legumain within the bone microenvironment is required for understanding its biological role in skeletal homeostasis.

Osteoporosis is a systemic bone disease, characterized by decreased bone formation, reduced bone mass, and disruption of normal bone architecture, resulting in bone fragility and increased risk of fractures ([@bib15]). Legumain expression was elevated in hBMSCs from osteoporotic patients and, at single-cell resolution, legumain overexpression in ADs inversely correlated with local trabecular bone volume. Bioinformatic analysis revealed the presence of *NF-κB* binding sites in the legumain promoter, suggesting that the proinflammatory cytokines (e.g., *TNF-α* and *IL6*), known to be upregulated in osteoporotic bone marrow microenvironment ([@bib10]), could regulate legumain expression.

In summary, our findings identified legumain as a "molecular switch" with opposing effects on bone and fat formation by hBMSCs through degradation of the ECM protein fibronectin ([Figure 6](#fig6){ref-type="fig"}F) and that altered expression of legumain in the bone microenvironment contributes to the pathophysiology of trabecular bone loss in osteoporosis. Finally, our data suggest that inhibition of legumain activity would be a promising approach to enhance bone regeneration.

Experimental Procedures {#sec4}
=======================

Cell Culturing, Differentiation, and siRNA Transfection {#sec4.1}
-------------------------------------------------------

We have employed our well-characterized hBMSC-TERT cell line (as a model of hBMSC) established by ectopic expression of the catalytic subunit of human telomerase, as described previously ([@bib2], [@bib57]). Primary hBMSC cultures were established from bone marrow aspirates of osteoporotic patients and age-matched control subjects, as described before ([@bib39]). Informed consent was obtained from all donors and the study was approved by the Scientific Ethics Committee of the Region of Southern Denmark (issue no. 2003-41-3206, 2008-00-92). Cells were cultured in standard culture medium (SCM) containing minimal essential medium (MEM) (Invitrogen) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin (P/S) (Gibco) at 37°C in a humidified atmosphere containing 5% CO~2~. All employed cell types were regularly tested for mycoplasma contamination.

Cell culture plates were coated with collagen type 1 (6 μg/cm^2^; Sigma), gelatin (1 μg/cm^2^; Sigma), or fibronectin (1 μg/cm^2^; Sigma) and incubated at room temperature for 1 hr. The solution was then removed and the plates were air dried for 45 min, rinsed with PBS (without Ca^2+^ or Mg^2+^) followed by seeding cells.

For OB differentiation, 20 × 10^3^ cells/cm^2^ were seeded and induced with OB induction medium (OIM) containing 10 mM β-glycerophosphate (Calbiochem), 10 nM dexamethasone (Sigma), 50 μg/ml L-ascorbic acid (Wako Pure Chemicals Industries), 10 nM 1,25-dihydroxyvitamin D~3~ (LEO Pharma) in MEM supplemented with 10% FBS and 1% P/S. The medium was changed every third day. Control cells were cultured in SCM. Quantification of *ALP* activity and alizarin red staining were performed as described previously ([@bib32]).

For AD differentiation, cells were plated at a density of 35 × 10^3^ cells/cm^2^ and induced with adipogenic induction medium containing 10% horse serum (Gibco), 100 nM dexamethasone (Sigma), 500 nM insulin (Sigma), 1 μM BRL49653 (Sigma), and 0.25 mM 3-isobutyl-1-methylxanthine (Sigma) in MEM medium supplemented with 10% FBS and 1% P/S. The medium was changed every third day. Control cells were cultured in SCM. Oil red O staining of the accumulated lipid droplets in mature ADs was performed as described previously ([@bib32]).

Small interfering RNA (siRNA) transfection was carried out as described previously ([@bib32]). In brief, Lipofectamine 2000 was used as transfection reagent and a reverse-transfection protocol was employed according to the manufacturer\'s instructions (Invitrogen) and OB differentiation was induced 48 hr after siRNA transfection. Non-targeting no. 1 siRNA (Ambion) and siRNA against fibronectin (sense: GGCUCAGCAAAUGGUUCAGtt) (Ambion) were used at 25 nM ([@bib27]) ([@bib54]).

Legumain Activity Assay {#sec4.2}
-----------------------

Cells were washed with PBS and lysed using lysis buffer containing 1 mM disodium EDTA, 100 mM sodium citrate, 1% n-octyl-β-D-glucopyranoside (pH 5.8). The total protein concentration in the lysates was measured using Bradford assay ([@bib27]). To measure legumain activity, 10 μg total protein in a total volume of 20 μL was added to 100 μL of assay buffer (39.5 mM citric acid, 121 mM Na~2~HPO~4~, 1 mM Na~2~EDTA, 0.1% 3-\[(3-cholamidopropyl)dimethylammonio\]-1-propanesulfonate, and 1 mM DTT) in a dark 96-well plate, followed by adding 50 μL of peptide substrate (Z-Ala-Ala-Asn-AMC; 10 μM final concentration) (Bachem) in assay buffer as described previously ([@bib33]). The plate was then incubated at 30°C for 1 hr and the fluorescent intensity (380EX/460EM) was measured using a FLUOstar Omega multimode microplate reader.

Heterotopic Bone Formation Assay In Vivo {#sec4.3}
----------------------------------------

To evaluate the in vivo bone formation, 5 × 10^5^ cells of either sh*LGMN* or shCtrl cell lines were loaded on scaffolds containing 40 mg hydroxyapatite/tricalcium phosphate ceramic powder (Zimmer Scandinavia), incubated at 37°C overnight, and implanted subcutaneously on the dorsal side of 8-week-old female non-obese diabetic.CB17-Prkdc^scid^/J mice as described previously ([@bib3]). A simple randomization method was used to assign mice to different groups. After 8 weeks, implants (n = 4 implants/cell line) were retrieved and fixed in 4% formaldehyde for 24 hr, decalcified in formic acid for 3 days, and embedded in paraffin. sections (4 μm, n = 9/implant) were cut and stained with H&E(Bie & Berntsen). Bone volume per total volume was blindly quantified using pixel scoring method as described previously ([@bib3]). Human-specific vimentin staining (Thermo Scientific, RM-9120) was used to show that the bone formed in the implants was of human origin. Mice experiments were carried out in accordance with permissions issued by the Danish Animal Experiments Inspectorate (2012-DY-2934-00006).

Zebrafish Studies {#sec4.4}
-----------------

Zebrafish (*Danio rerio*) were housed at 28°C, in a 14 hr light and 10 hr dark cycle. Embryos were collected by natural spawning and raised at 28°C in E3 solution according to standard protocols ([@bib62]). A pair of TALENs recognizing exon 4 of the zebrafish *lgmn* gene were constructed by the platinum gate method ([@bib53]). lgmn_TAL1: NN-NG-NN-NG-NG-NG-NI-NN-NG-NI-NI-HD-HD-HD-NG-NI-HD. lgmn_TAL2: HD-HD-NI-NG-NG-NG-NN-NN-NG-HD-NG-NN-NG-NG. TALEN mRNA was synthesized by in vitro transcription using the T7 mMESSAGE mMACHINE Kit (Ambion). mRNA (125 pg) encoding each TALEN heterodimer was injected into the cytoplasm of the cell of one-cell-stage wild-type zebrafish embryos. Control injections used lgmn_TAL1 and an irrelevant TAL2. TALEN efficiency was monitored by HRMA using KAPA-HRM master mix (Kapa Biosystems) on an Eco Real-Time PCR machine (Illumina). HRMA_F: 5′-TGA TTT GTC AGT TCT TGC TCC TT-3′. HRMA_R: 5′-ACT TAC GTC CCC AAT GTA GTC C-3′. ON/OUT PCR was performed as described using HRMA_F + HRMA_R as outer primers and HRMA_F + lgmn_ON: 5′-CCA TTT GGT CTG TTT ATG ACC ACT-3′ for "ON" PCR ([@bib56]). Total RNA was extracted from cultured cells using TRIzol reagent (Invitrogen) and the aqueous phase was isolated by column purification (Zymo Research). qRT-PCR was performed using a KAPA One-Step Universal Master Mix (KAPA Biosystems) on an Eco Real-Time PCR machine (Illumina) using the ΔΔCT method. [Table S3](#mmc1){ref-type="supplementary-material"} shows the primers used for qRT-PCR. Alizarin red staining and blind quantifications of the vertebrae were performed as described previously ([@bib62]) and imaged with a Leica M165 FC microscope. SD-134 was added to E3 medium at 500 μM in 1% DMSO from 3 to 7 dpf. Simple randomization was used to assign the fish to SD-134 or DMSO groups. The use and treatment of zebrafish in this project were in accordance with and approved by the Animal Ethics Review Committee, Garvan Institute of Medical Research.

Immunohistochemical Analyses of Human Bone Specimens {#sec4.5}
----------------------------------------------------

Bone biopsy specimens from 13 postmenopausal osteoporotic patients (mean age, 77 years; range, 68--86 years) and 11 age-matched controls (mean age, 75 years; range, 67--83 years) were included in the study ([@bib37]). In accordance with approval from the Danish National Committee on Biomedical Research Ethics (journal no S-2007.01.21), formal consent was not required for the controls, whose biopsies were included in the study retrospectively; oral and written informed content was obtained from the osteoporotic donors included in the study. Sections (3.5-μm thick) from the decalcified paraffin-embedded bone specimens from postmenopausal osteoporotic patients and controls were immunostained with mouse anti-legumain (1:400, Santa Cruz, SC-133234, clone B-8) antibodies, which were labeled with peroxidase-conjugated anti-mouse IgG polymers (1:10; DPVM110HRP, BrightVision). The signal was amplified with digoxigen-conjugated peroxidase-reactive tyramide (1:900; NEL748B001KT, Perkin-Elmer), labeled with alkaline-phosphatase-conjugated sheep anti-digoxigen (1:500; 11093274910, Roche), and visualized with Liquid Permanent Red (DAKO). The stained sections were counterstained with Mayer's hematoxylin and mounted with Aqua-Mount. The semi-quantitative analyses estimated the prevalence of cells with either weak (+1), moderate (+2), or strong (+3) staining within the different cell populations. We employed systematic random analysis for selection of visual fields following the central axis in the biopsies. The H score (range, 0--300) was calculated using the previously published equation ([@bib4], [@bib20]). H score = ∑Pi × i, where i is the staining intensity (0--3) and Pi is the percentage of cells stained with each intensity (0%--100%).

Statistical Analysis {#sec4.6}
--------------------

Statistical analyses were performed using Prism 6.0 (GraphPad) or Microsoft Excel 2010. Data are represented as mean ± SD of at least three independent experiments, unless otherwise stated. Normal distribution of the data was tested using the D\'Agostino-Pearson omnibus normality test. Testing for statistical differences between variables was carried out using two-tailed unpaired Student's t test on the normally distributed data. Statistical differences between variables that did not follow normal distribution were determined using the Mann-Whitney test. Linear regression analysis and the Spearman correlation coefficient (r) were employed for the correlation analyses. p ≤ 0.05 was considered statistically significant.
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![Regulation of Legumain Expression during In Vitro and In Vivo Differentiation of Human Bone Marrow Stromal Cells\
(A and B) Immunohistochemical (A) and RNA in situ hybridization (B) analysis of legumain expression and localization in normal human iliac crest bone biopsies. n = 11 donors. Scale bar, 50 μm. Red arrows, canopy cells; black arrows, reversal cells; arrow heads, osteoclasts; v, vessel.\
(C) qRT-PCR analysis of *LGMN* expression during osteoblast (OB) differentiation of hBMSCs at 6, 12, and 18 days (D6--D18) after start of differentiation (day 0, D0). Data represent mean ± SD from three independent experiments. ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, two-tailed unpaired Student's t test.\
(D) Western blot analysis of legumain expression in cell lysates from hBMSC cultures during OB differentiation.\
(E) Quantification of the mature legumain (36 kDa) band intensity. Arbitrary units (ARBU). Data represent mean ± SD from three independent experiments. ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, two-tailed unpaired Student's t test.\
(F) Quantification of legumain activity in cell lysates from hBMSCs during OB differentiation. Data represent mean ± SD from three independent experiments. ^∗^p ≤ 0.05, two-tailed unpaired Student's t test.\
(G) qRT-PCR analysis of *LGMN* expression during adipocyte (AD) differentiation of hBMSCs. Data represent mean ± SD from three independent experiments. ^∗∗^p ≤ 0.01, two-tailed unpaired Student's t test.\
(H) Western blot analysis of legumain expression in cell lysates from hBMSC cultures during AD differentiation.\
(I) Quantification of the mature legumain (36 kDa) band intensity. Data represent mean ± SD from three independent experiments. ^∗^p ≤ 0.05, two-tailed unpaired Student's t test.](gr1){#fig1}

![Legumain Knockdown Enhanced Osteoblast Differentiation and In Vivo Bone Formation and Inhibited Adipocyte Differentiation of Human Bone Marrow Stromal Cells\
hBMSCs were stably transfected with control (shCtrl) or *LGMN* shRNA (sh*LGMN*).\
(A) qRT-PCR analysis of *LGMN* expression. Data represent mean ± SD from three independent experiments. ^∗^p ≤ 0.05, two-tailed unpaired Student's t test.\
(B) Western blot analysis of legumain and *GAPDH* control. Data represent three independent experiments.\
(C) Quantification of legumain activity. Data represent mean ± SD from three independent experiments. ^∗∗^p ≤ 0.01, two-tailed unpaired Student's t test.\
(D) Quantification of alkaline phosphatase (ALP) activity in the presence of standard culture medium (SCM) or osteoblast induction medium (OIM) (day 6). Data represent mean ± SD from three independent experiments. p \> 0.05, two-tailed unpaired Student's t test.\
(E) qRT-PCR gene expression analysis of the early (*ALP*, *Col1a1*) and late (*BGLAP*, *IBSP*) OB marker genes. Data represent mean ± SD from three independent experiments. ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, two-tailed unpaired Student's t test.\
(F) Quantification of alizarin red staining at day 12. Data represent mean ± SD from three independent experiments. ^∗^p ≤ 0.05, two-tailed unpaired Student's t test.\
(G and H) Quantification of accumulated lipid droplets in the presence of AD induction medium using oil red O staining (day 12). Scale bar, 150 μm, Data represent mean ± SD from three independent experiments. ^∗^p ≤ 0.05, two-tailed unpaired Student's t test.\
(I) qRT-PCR gene expression analysis of the AD marker genes *PPARG2*, *FABP4*, *LPL*, and *ADIPOQ*. Data represent mean ± SD from three independent experiments. ^∗^p ≤ 0.05, two-tailed unpaired Student's t test.\
(J) Histological analysis of in vivo bone formation by hBMSCs stably transfected with non-targeting control shRNA (shCtrl) or *LGMN* shRNA (sh*LGMN*), 8 weeks after implantation in immune-deficient mice. Arrows, hydroxyapatite; arrow heads, bone. Scale bars: top panels, 500 μm; bottom panels, 250 μm.\
(K) Quantification of the heterotopic bone formation, n = 4 implants for each cell type, Data represent mean ± SEM. ^∗^p ≤ 0.05, Mann-Whitney test.\
(L) Human-specific vimentin staining of sh*LGMN* implants. Arrows, hydroxyapatite; arrow heads, bone. Scale bars: top panels, 500 μm; bottom panels, 250 μm. ab, antibody.\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.](gr2){#fig2}

![Legumain Overexpression Inhibited Osteoblast and Enhanced Adipocyte Differentiation of Human Bone Marrow Stromal Cells\
See also [Figure S1](#mmc1){ref-type="supplementary-material"}.\
(A--C) Legumain (*LGMN*)-transduced hBMSCs was established using a retroviral transduction system and the successful overexpression of legumain was confirmed using (A) qRT-PCR analysis of *LGMN* mRNA expression, (B) western blot analysis of legumain in cell lysate, and (C) quantification of legumain activity. Data represent mean ± SD from three independent experiments. ^∗∗^p ≤ 0.01, two-tailed unpaired Student's t test.\
(D--G) Secretion of legumain in the conditioned medium (CM) was evaluated using (D) ELISA measurement (data represent mean from three technical replicates) and (E) western blot analysis of legumain in the CM from hBMSC-*LGMN*-overexpressing cell line (*LGMN*-CM) (data represent three independent experiments). To assess the effects of legumain on OB differentiation, control hBMSCs containing empty vector (E.V.) and hBMSC-*LGMN* cell lines were cultured in OB induction medium, and expressions of OB marker genes were analyzed using qRT-PCR (F) and mineralized matrix formation was determined by quantification of eluted alizarin red staining (G). Data represent mean ± SD from three independent experiments. ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, two-tailed unpaired Student's t test.\
(H and I) To assess the effect of legumain on AD differentiation, control hBMSCs and hBMSC-*LGMN* cell lines were cultured in AD induction medium, and (H), (I) accumulation of lipid droplets was measured by quantification of the eluted oil red O staining, ^∗^p ≤ 0.05, two-tailed unpaired Student's t test. Scale bar, 150 μm.\
(J) Expressions of AD marker genes were measured by qRT-PCR (day 7). Data represent mean ± SD from three independent experiments. ^∗^p ≤ 0.05, two-tailed unpaired Student's t test. E.V., empty vector; *LGMN*, legumain-overexpressing hBMSCs.](gr3){#fig3}

![Legumain Degrades Fibronectin in Human Bone Marrow Stromal Cell cultures\
(A) Western blot analysis of legumain and fibronectin in cell lysates of hBMSC lines with stable knockdown of legumain (sh*LGMN*) during ex vivo OB differentiation (day 0--7).\
(B and C) Quantification of protein band intensities in (A). ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, two-tailed unpaired Student's t test.\
(D) Western blot analysis of legumain and fibronectin in cell lysates of hBMSC lines with stable overexpression of legumain (*LGMN*) during ex vivo OB differentiation (day 0--7).\
(E and F) Quantification of protein band intensities in (D). Data represent mean ± SD from three independent experiments. ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, two-tailed unpaired Student's t test.\
(G) Western blot analysis of human fibronectin degradation by purified legumain from bovine kidneys (bLeg; 10:1 w/w; control) and the cell lysates from hBMSCs stably transfected with E.V. or legumain (*LGMN*; legumain overexpression).\
(H) Quantitation of mineralized matrix formation on day 15 of OB differentiation, in the presence of siRNA against fibronectin (si*FN*) and non-targeting control siRNA (siCtrl). Data represent mean ± SD from three independent experiments. ^∗∗^p ≤ 0.01, two-tailed unpaired Student's t test.\
(I and J) Effect of different ECM proteins (gelatin, collagen 1, or fibronectin) on mineralized matrix formation by hBMSCs visualized by alizarin red staining and quantification. Data represent mean ± SD from three independent experiments. ^∗^p ≤ 0.05, ^∗∗^p ≤ 0.01, two-tailed unpaired Student's t test.\
See also [Figure S2](#mmc1){ref-type="supplementary-material"}.](gr4){#fig4}

![Legumain Inhibits OB Differentiation and Bone Mineralization In Vivo\
(A) Conservation of zebrafish *lgmn*. I, amino acid identity; S, amino acid similarity.\
(B) High-resolution melting analysis of pooled *lgmn*-TALEN and control-injected animals at 3 days post-fertilization (dpf).\
(C) qRT-PCR analysis of OB and AD marker genes at 5 dpf. Data represent mean ± SEM of three pools of ten animals. ^∗^p ≤ 0.05, two-tailed unpaired Student's t test.\
(D and E) Control and *lgmn* mutant animals at 7 dpf. Scale bars, 500 μM. (D) Bright field and (E) fluorescent alizarin red staining. (E′ and E″) Higher-magnification images of boxed regions. Arrowheads, whole vertebrae stained; arrows, partial vertebrae stained. Scale bars, 100 μM.\
(F) Number of alizarin-red-stained vertebrae in *lgmn* and control animals at 7 dpf. Data represent mean ± SEM, n \> 30 for each group. ^∗^p ≤ 0.05, ^∗∗∗^p ≤ 0.005 two-tailed unpaired Student's t test.\
(G) Animals were treated with SD-134 (500 μM) or 1% DMSO from 3 to 7 dpf. Number of alizarin-red-stained vertebrae at 7 dpf. Data represent mean ± SEM, n = 12 for each group. ^∗∗∗^p ≤ 0.005 two-tailed unpaired Student's t test.](gr5){#fig5}

![Effect of Aging and Osteoporosis on Legumain Protein Levels in Human Serum and Bone Microenvironment\
(A) Serum legumain levels in 89 women, aged 48--87 years, p \< 0.0001 using Spearman correlation analysis.\
(B) Western blot analysis of mature legumain (36 kDa) and *GAPDH* in cell lysates from primary hBMSC cultures established from bone marrow aspirates of osteoporotic patients (n = 5) and age-matched controls (n = 3).\
(C) Quantification of western blot band intensities normalized to *GAPDH*. Data represent mean ± SD from three independent experiments. ^∗∗∗^p ≤ 0.005, two-tailed unpaired Student's t test.\
(D) Upper panel: legumain staining of bone biopsies from postmenopausal osteoporotic patients (n = 11) and age-matched control individuals (n = 13). Scale bars, 1 mm. Lower panel: higher-magnification images of the boxed regions. Scale bars, 50 μm.\
(E) Correlation of trabecular bone area with legumain expression by adipocytes in biopsies from postmenopausal osteoporotic patients (n = 80 random regions of interest \[ROI\] = 1 mm^2^), p = 0.004 using Spearman correlation analysis.\
(F) Proposed mode-of-action of legumain for regulation of hBMSC lineage commitment.](gr6){#fig6}
